Live Breaking News & Updates on Enariniwill Receive Payments Including Milestones And Tiered Royalty On Sales Sciclone Will Be Responsible For Conducting Funding Local Clinical Development As Well Commercialization Of Vaborem To Facilitate Access Patients In China

Vaborem, a patented combination of meropenem and vaborbactam, is expected to address the rising prevalence of carbapenem-resistant Klebsiella pneumoniae (CRKP) infections in China The deal brings together Melinta's innovation, Menarini's cross-regional expertise in registration and marketing this asset, and SciClone's development and commercial presence in China Menarini will receive a total payment of up to 115 million, which includes milestone payments and tiered royalty on net sales, during the term SINGAPORE, Sept. 20, 2022 /PRNewswire/ A. Menarini Asia-Pacific Holdings Pte. Ltd., part of The Menarini Group, and SciClone Pharmaceuticals (Holdings) Limited have entered into an exclusive licensing agreement to develop and commercialize Vaborem (meropenem and vaborbactam) in the People's Republic of China (China). This initiative serves to expand options to address the public health threat of antimicrobial resistant infections, specifically carbapenem-resistant Enter ....

United States , Chong Zhao , Christine Ann Miller , Maurizio Luongo , Menarini Asia Pacific , Sciclone Pharmaceuticals Holdings Limited , Sourcea Menarini Asia Pacific Holdings Pte , World Health Organization , China Antimicrobial Surveillance Network , Sciclone Pharmaceuticals Holdings , European Union , Menarini Group , Sciclone Pharmaceuticals , Prnewswirea Menarini Asia Pacific Holdings Pte , Melinta Therapeutics , Menarini Asia Pacific Holdings , Chief Executive Officer , License Agreement , Independent States , Clone Pharmaceuticals , Cidara Therapeutics , Asia Pacific Holdings , A Patented Combination Of Meropenem And Vaborbactam , S Expected To Address The Rising Prevalence Of Carbapenem Resistant Klebsiella Pneumoniae Crkp Infections In China Deal Brings Together Melinta 39s Innovation , Enarini 39s Cross Regional Expertise In Registration And Marketing This Asset , Nd Sciclone 39s Development And Commercial Presence In China Menarini Will Receivea Total Payment Of Up To 115 Million ,